A Randomized Phase III Study of Arfolitixorin versus Leucovorin with 5-Fluorouracil, Oxaliplatin, and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer: The AGENT Trial

by on 10 de juny de 2024 with No hi ha comentaris
  • Tabernero, J., Yoshino, T., Stintzing, S., de Gramont, A., Gibbs, P., Jonker, D. J., . . . Lenz, H. J. (2024). A Randomized Phase III Study of Arfolitixorin versus Leucovorin with 5-Fluorouracil, Oxaliplatin, and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer: The AGENT Trial. Cancer Research Communications, 4(1), 28-37. https://doi.org/10.1158/2767-9764.crc-23-0361

Deixa un comentari

L'adreça electrònica no es publicarà. Els camps necessaris estan marcats amb *